Data Sheet 1_Emotional prompting amplifies disinformation generation in AI large language models.docx by Rasita Vinay (21006911)

“…Introduction<p>The emergence of artificial intelligence (AI) large language models (LLMs), which can produce text that closely resembles human-written content, presents both opportunities and risks. …”

Feasibility of AI-powered assessment scoring: Can large language models replace human raters? by Michael Jaworski III (22156096)

“…<p><b>Objective:</b> To assess the feasibility, accuracy, and reliability of using ChatGPT-4.5 (early-access), a large language model (LLM), for automated scoring of Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) protocols. …”

GPT-4 results in decreased error rate for all tasks with increasing complexity when compared to GPT-3.5-turbo. by Jacqueline A. Jansen (14894276)

ANN architecture. by Abdelfattah Dani (22226715)

ANN architecture and configuration. by Abdelfattah Dani (22226715)

Illustration of BSC control using ANN for WECS. by Abdelfattah Dani (22226715)

Performance comparison between the OTC-FOC and ANN-BSC. by Abdelfattah Dani (22226715)

Training process flowchart of ANN-based MPPT controller. by Abdelfattah Dani (22226715)

Presentation 1_Tracking priming-induced language recovery in aphasia with pre-trained language models.zip by Yan Cong (1491478)

Data Sheet 1_Tracking priming-induced language recovery in aphasia with pre-trained language models.zip by Yan Cong (1491478)

THD for the stator current i_sb (ANN-BSC). by Abdelfattah Dani (22226715)

ANN-BSC outcomes: (a) PMSG currents, (b) Zoom-in illustration. by Abdelfattah Dani (22226715)

Mean values and 95% confidence intervals for recovery time, Average NN Interval (AVNN); Standard Deviation of NN Intervals (SDNN), Low Frequency/ High Frequency Ratio (LF/HF); and... by Robert Trybulski (10998702)

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects: